Cancer came as no surprise for one survivor.
Learn how the family history and a genetic syndrome put them at high risk.
Delving into the role of genetic counsellors in cancer care.
And the hope for a vaccination.
Category: Screening
Lynch Syndrome
Lynch syndrome is an inherited condition that increases the risk of developing certain cancers, including colorectal, endometrial, and ovarian cancer.
On this page
- What is Lynch syndrome?
- Which genes are involved?
- How common is Lynch syndrome?
- Which cancers are seen in people with Lynch syndrome?
- What is the risk of cancer in people with Lynch syndrome?
- Family history and Lynch syndrome
- Testing for Lynch syndrome
- What you can do if you have Lynch syndrome?
- More information
https://www.canceraustralia.gov.au/impacted-by-cancer/lynch-syndrome#what-is-lynch-syndrome
After Being Declared Cancer-Free
Most people believe that once a person is declared to be cancer-free that all is over.
Long after the doctor has given you this wonderful news, you still think about your journey and wonder if the cancer will come back. But, you keep these thoughts in your mind and live with this sense of fear always lingering in the back of your mind wondering if you just might be one of the very few for whom the cancer will return.
Being realistic, just about every survivor will think about this on occasion. When it comes time for yearly testing, you pray and hope beyond hope that nothing new will be discovered. This is perfectly natural but if you find yourself having these thoughts frequently, it is time to do yourself a favor and seek professional help.
World GO Day Planned Activities in Ireland
New UKCGG gene specific guidance
New UK Cancer Genetics Group(UKCGG) gene specific guidance to incorporate updated advice about risk-reducing aspirin.
For families with Lynch syndrome.
https://www.ukcgg.org/information-education/ukcgg-leaflets-and-guidelines/
Lynch Syndrome UK Conference 2025 -Highlights
Below you’ll find short summaries of each talk, with a link to the YouTube recordings on our YouTube channel, as well as links to additional useful resources at the end.
https://www.lynch-syndrome-uk.org/post/lynch-syndrome-conference-2025-highlights
Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis
Universal germline testing may not only transform the outlook for those with traditional hereditary cancer syndromes but also identify a wider range of associations and penetrance for germline variants.
If we are serious about winning the war against cancer, we need to have every bit of intelligence about it, both to treat cancer and to detect it early. The potential impact of the host should be considered in every patient with cancer.
Applying universal germline testing to patients with cancer routinely is one of the major opportunities that can revolutionise precision medicine practice and is needed to win the war against cancer (and possibly many other diseases).
What About the Cost?
Many arguments against testing are centered around the cost. Yet, the cost of germline testing (and next-generation sequencing in general) has markedly decreased over the past decade. Furthermore, patients get repeat routine prevention testing (mammograms, computed tomography scans for lung cancer, colonoscopies, or laboratory tests), which are quite expensive, compared with one time hereditary testing cost, which may be invaluable for the patient over an entire lifetime and informative for their family.
In addition, the cost of the test must be weighed against the cost of expensive (and possibly futile) therapy the patient will be subjected to because this genetic information was not available in a timely manner.
Lynch Syndrome UK – New Website
Check out their newly launched version….lots of information that you might find useful.
The diagnostic accuracy of the faecal immunochemical test(FIT) for the detection of early-onset colorectal cancer: an age-stratified analysis in South West England
The faecal immunochemical test (FIT) is a diagnostic triage tool for patients presenting with clinical features of CRC in primary care, though its performance in individuals under 50 years is not well established.
Conclusions: FIT performs excellently for patients aged 40-49; however, it may not be used optimally in patients <40 years. A more targeted strategy is needed to guide investigation in younger patients.
Gene-Specific Detection Rate of Adenomas and Advanced Adenomas in Lynch Syndrome
Colonoscopy is expected to reduce colorectal cancer (CRC) incidence in Lynch syndrome (LS) by detecting and removing adenomas. The existence of gene-specific differences in adenoma detection has been proposed yet remains insufficiently explored.
Conclusions
Carriers of MLH1/MSH2 pathogenic variants are at a higher risk of developing AAs compared with those with MSH6/PMS2 mutations, with MSH6 carriers exhibiting an intermediate risk profile. Advanced adenomas(AA) are an independent risk factor for post-colonoscopy CRC . LS patients with AAs should be identified as high risk and undergo enhanced colonoscopy surveillance.
https://www.sciencedirect.com/science/article/abs/pii/S001650852500650X?dgcid=author
Lynch Syndrome Ireland 